tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure Patients

Story Highlights
  • Shield Therapeutics’ study shows improved haemoglobin and quality of life with FeRACCRU®.
  • Ferric maltol could be a viable oral alternative to intravenous iron therapies for heart failure.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure Patients

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shield Therapeutics ( (GB:STX) ) has issued an update.

Shield Therapeutics announced positive results from the ORION-HF study, which demonstrated significant improvements in haemoglobin levels, exercise capacity, and quality of life for patients with heart failure and iron deficiency anemia treated with FeRACCRU® (ferric maltol). These findings, published in the European Journal of Heart Failure, highlight the potential of ferric maltol as an effective oral alternative to intravenous iron therapies, addressing a significant unmet need in the treatment of heart failure. The study’s results are consistent with previous research and could enhance Shield’s market positioning and stakeholder interest in the therapeutic benefits of ACCRUFeR®/FeRACCRU®.

The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with or without anemia. The company offers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative oral therapy that provides a novel mechanism of absorption compared to other oral iron therapies. Shield has launched ACCRUFeR® in the U.S. through a collaboration with Viatris and has licensed rights to various pharmaceutical companies for commercialization in regions including Europe, China, and Japan.

Average Trading Volume: 2,420,418

Technical Sentiment Signal: Hold

Current Market Cap: £83.96M

See more insights into STX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1